More than 10% of patients undergoing a simple inguinal hernia repair have neuropathic pain at the site two years postsurgery. The presence of the persistent pain does not appear though to depend on either surgical technique or the extent of damage to the ilioinguinal nerves. These findings suggest that a genetic component contributes to the risk of developing post-surgical neuropathic pain. Transection of the peripheral axons of primary sensory neurons results in alterations in their metabolism, regenerative capacity, survival, excitability and transmitter function, and we find using microarrays, that many hundreds of genes are regulated in the dorsal root ganglion following a peripheral nerve injury (Costigan et al, 2002). A major challenge is to identify which of the injury-regulated genes establish and maintain the pain, and whether the genes contributes to an increased susceptibility to develop neuropathic pain. To address this issue we have perfomed a pilot study using whole genome expression arrays to study the transcription profiles of DRGs in two closely related strains of rats with different neuroapthic pain phenotypes. We examined rats congenic for a high or a low autotomy phenotype following peripheral nerve transection (HA and LA respectively). Of 31,000 transcripts assayed in the DRG of naive and nerve-injured HA and LA rats, we find two that show a significant differential regulation between the strains; a full length EST with no known homology and a serine protease inhibitor. The protease inhibitor is substantially upregulated in the LA (low neuropathic pain sensitivity) strain and not in the HA (high neuropathic pain sensitivity) rats. Serine proteases activate bradykinin as well as many other neuoractive proteins and have been implicated in producing neuropathic pain. We hypothesise that the serine protease inhibitor regulates the level of axonal hypersensitivity and ectopic activity after nerve injury. To study this we propose to: 1. Characterize the expression of the serine protease inhibitor within the DRGs of HA / LA rats and in C57/BI6 / DBA/2 mice, both in naive animals and after nerve injury, and 2.Characterize the serine protease inhibitor's function in vivo using conditional overexpressing transgenic animals. We will create transgenic mice that will express the serine protease inhibitor at high levels in sensory neurons or non neuronal cells following nerve injury, and predict that this should, by mimicking the expression in the LA rats, decrease pain hypersensitivity in diverse neuropathic models.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Small Research Grants (R03)
Project #
1R03NS052623-01
Application #
6964036
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Program Officer
Porter, Linda L
Project Start
2005-07-01
Project End
2007-06-30
Budget Start
2005-07-01
Budget End
2006-06-30
Support Year
1
Fiscal Year
2005
Total Cost
$86,000
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Vicuña, Lucas; Strochlic, David E; Latremoliere, Alban et al. (2015) The serine protease inhibitor SerpinA3N attenuates neuropathic pain by inhibiting T cell-derived leukocyte elastase. Nat Med 21:518-23
Mills, Charles D; Allchorne, Andrew J; Griffin, Robert S et al. (2007) GDNF selectively promotes regeneration of injury-primed sensory neurons in the lesioned spinal cord. Mol Cell Neurosci 36:185-94
Griffin, Robert S; Costigan, Michael; Brenner, Gary J et al. (2007) Complement induction in spinal cord microglia results in anaphylatoxin C5a-mediated pain hypersensitivity. J Neurosci 27:8699-708
Tegeder, Irmgard; Costigan, Michael; Griffin, Robert S et al. (2006) GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat Med 12:1269-77